These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 11952859

  • 1. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
    Pomplun S, Wotherspoon AC, Shah G, Goldstraw P, Ladas G, Nicholson AG.
    Histopathology; 2002 Feb; 40(2):152-8. PubMed ID: 11952859
    [Abstract] [Full Text] [Related]

  • 2. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
    Kuo TT, Chan JK.
    Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
    [Abstract] [Full Text] [Related]

  • 3. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC, Chen PC, Chou TY, Chiang H.
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
    Su XY, Wang WY, Li JN, Liao DY, Wu WL, Li GD.
    Int J Clin Exp Pathol; 2015 Nov; 8(5):5354-62. PubMed ID: 26191237
    [Abstract] [Full Text] [Related]

  • 5. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma.
    Hishima T, Fukayama M, Hayashi Y, Fujii T, Arai K, Shiozawa Y, Funata N, Koike M.
    Hum Pathol; 1998 Apr; 29(4):330-8. PubMed ID: 9563781
    [Abstract] [Full Text] [Related]

  • 6. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
    Walts AE, Hiroshima K, Marchevsky AM.
    Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
    [Abstract] [Full Text] [Related]

  • 7. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT.
    Cancer; 2001 Oct 25; 93(5):330-6. PubMed ID: 11668468
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
    Nonaka D, Henley JD, Chiriboga L, Yee H.
    Am J Surg Pathol; 2007 Jul 25; 31(7):1038-44. PubMed ID: 17592270
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
    Dorfman DM, Shahsafaei A, Miyauchi A.
    Mod Pathol; 1998 Oct 25; 11(10):989-94. PubMed ID: 9796728
    [Abstract] [Full Text] [Related]

  • 11. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
    Dorfman DM, Shahsafaei A, Chan JK.
    Am J Surg Pathol; 1997 Aug 25; 21(8):936-40. PubMed ID: 9255257
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R.
    Chest; 2005 Jul 25; 128(1):140-4. PubMed ID: 16002927
    [Abstract] [Full Text] [Related]

  • 13. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
    Hayashi A, Fumon T, Miki Y, Sato H, Yoshino T, Takahashi K.
    J Clin Exp Hematop; 2013 Jul 25; 53(1):9-19. PubMed ID: 23801129
    [Abstract] [Full Text] [Related]

  • 14. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material.
    Kalhor N, Zander DS, Liu J.
    Mod Pathol; 2006 Aug 25; 19(8):1117-23. PubMed ID: 16680154
    [Abstract] [Full Text] [Related]

  • 15. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
    Chan JK, Tsang WY, Seneviratne S, Pau MY.
    Am J Surg Pathol; 1995 Oct 25; 19(10):1115-23. PubMed ID: 7573670
    [Abstract] [Full Text] [Related]

  • 16. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
    Weissferdt A, Tang X, Wistuba II, Moran CA.
    Mod Pathol; 2013 Dec 25; 26(12):1554-60. PubMed ID: 23787439
    [Abstract] [Full Text] [Related]

  • 17. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
    Pan CC, Chen PC, Wang LS, Lee JY, Chiang H.
    Histopathology; 2003 Aug 25; 43(2):165-72. PubMed ID: 12877732
    [Abstract] [Full Text] [Related]

  • 18. Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum.
    Saad RS, Landreneau RJ, Liu Y, Silverman JF.
    Appl Immunohistochem Mol Morphol; 2003 Jun 25; 11(2):107-12. PubMed ID: 12777991
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
    Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A.
    Mod Pathol; 2009 Oct 25; 22(10):1341-50. PubMed ID: 19648882
    [Abstract] [Full Text] [Related]

  • 20. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
    Tateyama H, Eimoto T, Tada T, Hattori H, Murase T, Takino H.
    Am J Clin Pathol; 1999 Feb 25; 111(2):235-40. PubMed ID: 9930146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.